混合试验显示,色皮患者的外皮皮肤炎显著改善。 Dupixent trial shows significant improvements in atopic dermatitis for patients with skin of color.

在第四阶段试验中,Dupixent (depilumab) 显示色皮肤患者的外皮皮肤炎症状有显著改善,在120名参与者中,76%的患者的病情严重程度提高了75%。 In a Phase 4 trial, Dupixent (dupilumab) showed significant improvements in atopic dermatitis symptoms for patients with skin of color, achieving a 75% improvement in disease severity for 76% of the 120 participants. DISCOVER试验也注意到了痒、高血压和干皮肤的减少,其安全情况与以往的研究一致。 The DISCOVER trial also noted reductions in itch, hyperpigmentation, and dry skin, with a safety profile consistent with previous studies. 本研究强调该药物对皮肤学研究中往往得不到充分服务的人口的潜在好处。 This study highlights the drug's potential benefits for a population often underserved in dermatological research.